TriNav Infusion System for the Evaluation of the Alignment between Planned Y90-Microspheres Dose and Delivered Y90-Microspheres Dose among Patients with Unresectable Primary or Metastatic Liver Cancers
This clinical trial uses the TriNav Infusion System (TriNav catheter) to evaluate the agreement (alignment) between the planned yttrium Y-90 (Y90)-microsphere radioembolization treatment dose and the actual treatment dose delivered to patients with liver cancer that cannot be removed by surgery (unresectable). Radioembolization is type of radiation therapy used to treat primary or secondary liver cancer. A thin, flexible tube is used to inject tiny beads that hold the radioactive substance Y90 into the main blood vessel that carries blood to the liver. The beads collect in the tumor and in blood vessels near the tumor, and the Y90 gives off radiation. This destroys the blood vessels that the tumor needs to grow and kills the cancer cells. When receiving radioembolization therapy, the treatment will be planned, including a targeted (or surrogate) dose of radiation agent. Sometimes because of the way radioembolization is delivered, the dose of radiation that reaches the tumor may not be the dose of radiation planned. Some researchers think this could be, in part, because of the type of catheter used to deliver the radiation treatment. This study may help researchers learn if using the TriNav catheter instead of standard catheter for the injection of the surrogate/test dose during the planning part of the radioembolization procedure matches better with the actual treatment with the radioactive microspheres.